REVIEW Genomic and Proteomic Biomarker Discovery in Neurological Disease

Biomarker insights 02/2008; 3(3).
Source: DOAJ


Technology for high-throughout scanning of the human genome and its encoded proteins have rapidly developed to allow systematic analyses of human disease. Application of these technologies is becoming an increasingly effective approach for identifying the biological basis of genetically complex neurological diseases. This review will highlight significant findings resulting from the use of a multitude of genomic and proteomic technologies toward biomarker discovery in neurological disorders. Though substantial discoveries have been made, there is clearly significant promise and potential remaining to be fully realized through increasing use of and further development of -omic technologies.

Download full-text


Available from: Travis Dunckley,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the last 30 years, the field of biomarkers has greatly expanded as early and specific endpoints for monitoring cellular responses to various disease states and exposures to drugs and chemical agents. They have enjoyed some success as predictors of health outcomes for a number of clinical diseases, but the application to chemical exposure risk assessments has been more limited. Biomarkers may be classified into categories of markers of exposure, effect, and susceptibility. Currently, "omics" biomarkers (i.e., genomic, proteomic, and metabolomic/metabonomic) are the major classes of biomarkers under development. These markers represent a continuum of cellular responses to drug or chemical exposures and provide linkages to mechanisms of cell injury/cell death or carcinogenic transformation. On the other hand, translation and application of these biomarkers for risk assessment has been limited due to validation and interpretation issues that need to be addressed in order for these potentially extremely valuable endpoints to reach their full potential as predictive tools for public health. This short chapter will briefly review these three "omics" biomarker classes and examine some validation/translation aspects needed in order for them to reach their full potential and acceptance as valuable tools for application to risk assessment.
    EXS 09/2012; 101:459-70. DOI:10.1007/978-3-7643-8340-4_16
  • [Show abstract] [Hide abstract]
    ABSTRACT: The identification of secreted protein markers has been receiving great attention as part of the trend toward non-invasive biomarker discovery. In addition, certain cell membrane proteins are known to be released into the extracellular milieu via ectodomain shedding. As membrane proteins play an essential role in signaling pathways and because most of the cancer biomarkers approved by the FDA today are membrane shed proteins, a tool that can correctly predict these class shed protein is valuable. In this study, an in-house predictor, ShedP, was developed to predict the ectodomain shedding events of membrane proteins. ShedP is the first computational method to our knowledge to allow shed membrane protein prediction. By integrating ShedP with other state-of-the-art predictors, a screening pipeline, SecretePipe, has been created that is able to identify secreted non-membrane proteins based on signal peptides and to identify released membrane proteins based on ectodomain shedding. The predictive results using secretome datasets revealed that SecretePipe outperformed other state-of-the-art secreted protein predictors. When evaluated against released membrane proteins, SecretePipe performed better than other predictors in identifying membrane-bound released proteins due to the presence of ShedP. The SecretePipe showed a great potential to assist the identification of membrane-bound shed markers in biomarker discovery.
    Journal of Proteome Research 01/2013; 12(3). DOI:10.1021/pr3009012 · 4.25 Impact Factor